Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension
| Autor: | Edward A. Panacek, Mark A. Munger, Edward M. Bednarczyk, William F. Rutherford, Francisco M. Gonzalez, George Emmanuel, A. I. Hakki, Lynn Anderson, Sherrolyn G. Weed, Jeffrey A. Green |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Vasodilator Agents Microgram medicine.medical_treatment Population Diastole Blood Pressure Fenoldopam Kidney Critical Care and Intensive Care Medicine Dopamine agonist Heart Rate Heart rate medicine Humans Infusions Intravenous Adverse effect education Aged education.field_of_study Chemotherapy business.industry Hemodynamics Middle Aged Anesthesia Hypertension Female 2 3 4 5-Tetrahydro-7 8-dihydroxy-1-phenyl-1H-3-benzazepine business Fenoldopam Mesylate medicine.drug |
| Zdroj: | Critical Care Medicine. 18:502-504 |
| ISSN: | 0090-3493 |
| DOI: | 10.1097/00003246-199005000-00008 |
| Popis: | To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 microgram/kg.min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (greater than or equal to 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p less than .001) with no significant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|